Israel's HMOs have already transformed health risk predictions in Israel through big data analysis. Now, the systems' abilities to integrate messaging and data is pushing the country to the top of the COVID-19 vaccine league table.
There is light at the end of the tunnel. After a difficult year for everyone, personally and professionally, the prospect of a level of normality returning in 2021 as the first batch of vaccinations are applied to those with the greatest need, is an enticing one.
There was a lot of optimism around at the start of 2020. Operators and investors we spoke to had a 'C' word on their lips. That word was consolidation. Whether it was the enticing prospect of consolidating the €26bn dental market, or IPOing the world's most internationally diversified for-profit service operators, HBI's digital pages were brimming with plans. Another 'C' word, sadly, had a different idea.
This week, an exclusive HBI report has uncovered a troubling statistic: people over the age of 80 were up to three times more likely to die of a COVID-19 infection in countries using rigid rationing guidelines that excluded the elderly from intensive care.
These are strange times. Two of the largest players in Europe are likely to IPO before the end of 2020. Meanwhile, advisers expect secondary sales to other funds run by the same PE house to account for up to half all sales.
Healthcare business opportunities are global. Sadly, as COVID has made all too apparent, risks can be global too. Next week, HBI has arranged an all-star virtual line-up to discuss the state of the regions, a three day event covering everywhere from CEE to China.
The use of telehealth peaked with the pandemic and is now tailing off across most of Europe. Most of the medical profession got stuck using 'primitive telehealth' like Skype so didn't see its full productivity potential. Austria has neglected the market providers and started to build its own - and there's a very strong argument for others to follow suit.
This is an auspicious time for the medicalised homecare sector, albeit for a tragic reason. Providers of drugs, medical equipment such as oxygen, and healthcare services to the patient's home see a COVID-fuelled boost in demand over the next few years.